The number of base drugs expanded to 900? Focus on infectious diseases, cancer drugs? What do these adjustment signals mean for pharmaceutical companies?

What will be the focus of the new version of the base drug catalogue? How will the adjustment of the base drug catalogue be better connected to the health care system? How should the balance of interests between medical institutions, pharmaceutical companies and patients be balanced? From the information currently available, the adjustment direction of the base drug catalog is disease-oriented, patients have no medicine available or need treatment for the disease, choose the most suitable drug into the catalog.
new version of the list of essential drugs may be adjusted from infectious disease medications, slow-disease and cancer tumor-to-slow-motion medications, and common disease medications to select appropriate essential drugs from listed medicines.
the national list of essential drugs, fast! On November 16th, the National Health and Wellness Commission organized a seminar in Chengdu on the management of the national base drug catalogue for comments (hereinafter referred to as the "seminar"), and the relevant competent departments such as the Drug Administration Department of the National Health And Wellness Commission, the Drug Catalog Office, the Sichuan Provincial Health And Wellness Commission and the Chengdu Health And Wellness Commission discussed with representatives of some pharmaceutical enterprises the relevant work on the revision of the management methods of the basic drug catalogue.
since the introduction of the basic drug system, the list of essential drugs in principle has been dynamically adjusted once every three years.
two years since the 2018 edition of the base drug catalogue was published, a new version of the base drug catalogue may be available in 2021.
will the list of base drugs be adjusted this time change? It has attracted the attention of the industry.
of this seminar, which was circulated in the new catalog "Good Things Near" industry, once again revealed the key direction of next year's adjustment of the base drug catalog.
has been updated three times so far.
the current implementation of the 2018 edition of the list of essential drugs compared with the previous two editions, no longer emphasize the basic, economics is not a priority factor to enter the list of essential drugs, and clinical value has become an important basis for selection.
the new version of the base drug catalog will pay more attention to product value and clinical endpoint indicators to improve the standard of cure, and ultimately improve the long-term quality of life of patients.
this seminar also proposed that the adjustment of the base drug catalog should be disease-oriented, patients without drugs available or need treatment for the disease, to choose the most appropriate drugs into the list.
Combined with the 2018 drug transfer standards, the new version of the base drug catalog may be adjusted from infectious diseases, chronic diseases and cancer tumors to slow disease drugs, as well as common disease drugs, from the listed drugs to select the appropriate basic drugs, effectively help the promotion of graded diagnosis and treatment.
fact, meetings and discussions on the essential drug system have become more frequent in the country since the beginning of the year.
In February, the National Health and Wellness Commission and six ministries jointly issued the Opinions on Strengthening pharmaceutical management in medical institutions to promote rational drug use, in which "1" is the base drug catalog, "X" is a non-essential drug, that is, on the basis of establishing the use of the base drug, according to the situation in various places to determine X, that is, the equipment and use of non-essential drugs.
986 policy, the proportion of basic drug-based drug varieties in primary medical institutions, secondary public hospitals and third-level public hospitals is not less than 90%, 80% and 60%.
this means that access to the list of essential drugs is crucial for pharmaceutical companies.
, the National Health and Wellness Commission held a meeting on the revision of the management methods of the base drug catalogue.
meeting proposed that the base drug will be combined with the chronic disease long prescription to establish the base drug core drug catalog.
industry generally believes that based on the core drug catalog established by combining base drugs with chronically ill prescriptions, perhaps an upgraded version of the 1-X drug model, the proportion of base drug use will increase further.
October, relevant departments organized a symposium on the basic drug system, organized relevant enterprises to participate in the meeting to discuss the basic drug policy issues, Chongqing Hieran, Taiji Group, Watson, Pharmaceutical Friends, AstraZeneta and other 13 pharmaceutical companies were invited to attend the meeting.
meeting to understand the implementation of the national basic drug system in various places and units, and solicited the revised recommendations of the National Basic Drug Catalog Adjustment Management Measures (Trial).
meeting also made it clear that the base drug does not represent low-cost drugs, there is clinical value of high-priced drugs can also be considered for inclusion in the list of base drugs.
, the adjustment of the base drug will not consider the enterprise's active declaration method, or the selection of clinical experts mainly.
entered November, and then came the news that on November 16th and 18th the relevant departments of the state will hold two seminars on the management methods of the base drug catalogue for comments, which shows that the adjustment of the list of the base drugs is being carried out in an intensive manner.
02 in or out? The industry, which affects the size of the hundreds of billions of market, generally believes that the base drug has both the attribute of medical insurance payment and the attribute of drug guidance.
the adjustment of the list of drugs, but also affect the hearts of pharmaceutical companies.
, on the other hand, the base drug catalog is seen as a miniature version of the health care catalog.
2,709 varieties in the 2019 edition of the Medicare Drug Catalog, while the 2018 edition of the List of Essential Medicines contains 685 drugs.
not on the medicare list from 11 at the beginning of the 685-drug catalog, to three remaining after the 2019 health-care adjustment.
commonality between the two catalogues is that the drugs included should generally have therapeutic value, reasonable price, safe and reliable, i.e. to meet safety, effectiveness and economy.
on the other hand, unlike the medical insurance catalogue, the base drug catalogue is a directory that places more weight on drug use guidance, is the way the country guides clinical drug use, and the catalog drug use highlights the basis of clinical common drug use.
At the same time, the list of essential drugs focuses on the attributes of drug use, and the countries that enter the catalogue encourage priority procurement and use and promote their use through measures to improve the price of essential medicines, as noted in the 2019 Opinion on FurtherIng the Work of Maintaining Prices for Shortage Drugs As a percentage, the proportion of basic drug varieties in primary health care institutions, secondary public hospitals and third-level public hospitals is not less than 90%, 80% and 60% respectively in principle, promoting medical institutions at all levels to form a "1 plus X" drug use model dominated by basic drugs.
At the same time, the number of basic drug products used has become an important assessment index in the performance appraisal system of level 2 and 3 hospitals, among which the proportion of basic drug prescriptions for outpatients, the proportion of basic drug use among inpatients, the proportion of basic drug procurement varieties, and the proportion of the proportion of the national organization's centralized procurement of drugs for the use of the winning drugs have been included.
whether it is the increase in the proportion of essential drugs in medical institutions at all levels in policy, or the promotion of the model of 1 x, the important role of the list of essential drugs will become more prominent in the pharmaceutical market in the future.
this is why there is a growing demand for dynamic adjustment programmes in the base drug catalogue.
In a 2020 work point of the Pharmaceutical Division of the National Health and Health Commission, "research and revise the management methods of the national basic drug catalogue, optimize the selection and adjustment procedures for the catalogue, and start the catalog adjustment work in due course" is one of the priorities of this year's Department of Pharmaceutical Administration.
For the "timely start of the catalog adjustment work", the industry generally believes that from the National Health Insurance Administration after the establishment of the dynamic adjustment of the health insurance catalog, the National Health Care Commission-led list of essential drugs will also take dynamic adjustment.
according to the development of disease, drug economy, new drug research and development, medical insurance negotiations and other factors, the adjustment of the base drug can actually be normalized, at any time to add and transfer out.
, the dynamic adjustment of the base drug catalogue is conducive to the rapid entry of new drugs into the market.
to this, the National Health and Wellness Commission proposed that dynamic adjustment in principle not more than three years, the newly listed efficacy is accurate, reasonable price, better than the existing drug efficacy of drugs, should be timely start adjustment procedures into the catalog.
the debate over the adjustment of the list of essential drugs in 2003, the industry also has its own opinions on the adjustment of the catalogue of base drugs.
first is the number of supplements to the list of base drugs.
According to the current national average of 1500 varieties of drugs in each triple-A hospital, if the number of base drug catalog products can reach 90%, 80%, 60% of the hospital staffing ratio requirements, industry insiders believe that the base drug catalog needs to be updated to 900 to meet the corresponding policy requirements.
Second, because the adjustment rules of the base drug catalog adopt the mode of transfer-in, transfer-out, which also means that more new drugs, through consistent evaluation of generic drugs will be given access to the base drug catalog to expand the market, and those safe and unused "old drugs" will accelerate the exit.
experts believe that whether drugs pass a consistent evaluation will also have a significant impact on whether drugs can enter or remain in the Catalog.
To this, the National Health and Safety Commission has made it clear that the base drug catalogue is the leader and carrier of the implementation of the basic drug system, the new approval and listing, effectiveness and safety evidence is clear, cost-effective more significant through the consistent evaluation of generic drugs, will be inclined to be included in the catalog;
In addition, some industry insiders pointed out that the core drug use catalog is also the focus of the next industry attention, the core drug use catalog will directly determine the upgrade of 1 x, slow disease range and major disease medication will be the biggest beneficiaries.
with the introduction of the 2021 edition of the base drug catalog and the base drug core drug catalog, those drugs that enter the base drug catalog but do not enter the base drug core drug catalog, or will be marginalized.
of the drug-based drug catalog, for pharmaceutical companies, is a big test.
will we focus on the new version of the base drug catalogue that we are calling out? How will the adjustment of the base drug catalogue be better connected to the health care system? How should the balance of interests between medical institutions, pharmaceutical companies and patients be balanced? On November 27th, at the 2020 'Chinese Pharmaceutical Entrepreneur Scientists Investors Conference in Hangzhou, the relevant person in charge of the Basic Medicines Division of the National Health And Wellness Commission will make more interpretations of the adjustment and management of the National Essential Medicines Catalog.
the future of the drug catalogue, we invite representatives from all parties to discuss it together!